跳至主要内容
临床试验/NCT02958514
NCT02958514已完成不适用

Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction

Peking University Third Hospital0 个研究点目标入组 20 人开始时间: 2016年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
20
主要终点
Ocular Surface Disease Index (OSDI)

研究概览

简要总结

This study aims to evaluate the efficacy of intense pulsed light in treating dry eye caused by meibomian gland dysfunction and make a comparison between the traditional treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
26 Years 至 78 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with dry eye syndrome and diagnosed as MGD

排除标准

  • an infection or inflammatory disease;
  • ocular surgical history with in the last 3 months
  • SGOGREN SYNDROME

研究组 & 干预措施

traditional treatment group

Other

Subjects in this group are treated by tobramycin and dexamethasone ophthalmic ointment qn and artificial tears qid.

干预措施: Tobramycin and Dexamethasone Ophthalmic Ointment (Drug)

IPL treatment group

Experimental

Subjects in this group are treated with 3 cycles of intense pulsed light of 4 weeks interval and artificial tears qid.

干预措施: intense pulsed light (Device)

结局指标

主要结局

Ocular Surface Disease Index (OSDI)

时间窗: through study completion,an average of 6 months

normal value:\<13 abnormal value:≥ 13

次要结局

  • Corneal Fluorescein Stain(CFS)(through study completion,an average of 6 months)
  • Eyelid ester discharge ability score(through study completion,an average of 6 months)
  • Eyelid ester trait ratings(through study completion,an average of 6 months)
  • breakup time of tear film (BUT)(through study completion,an average of 6 months)
  • The concentrations of inflammatory cytokines such as IL-1、IL-6 and IL-8(through study completion,an average of 6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hong Qi

MD.PHD.

Peking University Third Hospital

相似试验